drugset / Trial / NCT07600762

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants

NCT07600762

Phase 1 Completed 12 enrolled AbbVie
RandomizedParallel-groupDouble-blindBasic science

Summary

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants

Timeline

Start
2026-04-21
Primary completion
2026-06-17
Completion
2026-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Nacresertib Small molecule Oral

Indications

No indication recorded.